Paul Smaltz, Senior Vice President of BASF Pharma Solutions, explains how the company acts as a strategic partner to the ...
SK pharmteco is a global CDMO, with locations in the US, EU, and South Korea. The company’s core capabilities center on small ...
As a part of PDA Week 2026, Christopher Lewis, Emoja Biopharma and president of the Mountain States PDA Chapter, reflects on ...
European Biotechs are utilizing AI and precision medicines to improve the personalized treatment of cardiovascular disease.
Financial terms include $40 million upfront for four programs, expansion options, and opt-out economics up to $535 million per program plus low double-digit royalties, totaling up to $2.1 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results